- Conditions
- Sleep Restriction
- Interventions
- Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Torrance, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Opioid-use Disorder, Opioid Withdrawal
- Interventions
- Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone
- Device · Drug
- Lead sponsor
- Spark Biomedical, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 4
- States / cities
- Rancho Mirage, California • Crownsville, Maryland • Center City, Minnesota + 1 more
- Conditions
- Sleep Restriction
- Interventions
- Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
- Drug
- Lead sponsor
- Peter y. Liu
- Other
- Eligibility
- 22 Years to 45 Years · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment, HIV-Associated Cognitive Motor Complex
- Interventions
- Scopolamine Injectable Product, Mecamylamine Pill
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 1 Diabetes, New Onset
- Interventions
- Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 9 Years to 20 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 10
- States / cities
- San Francisco, California • New Haven, Connecticut • Gainesville, Florida + 7 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar
- Drug
- Lead sponsor
- Epitopoietic Research Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 3
- States / cities
- Orange, California • Boston, Massachusetts
- Conditions
- HIV Prevention
- Interventions
- Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg
- Drug
- Lead sponsor
- CONRAD
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Norfolk, Virginia
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Pain
- Interventions
- multimodal:acetaminophen, gabapentin, ketamine, bupivacaine, placebo pills and injectables
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
- Interventions
- Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo
- Drug
- Lead sponsor
- Kalie Tommerdahl
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Seattle, Washington